Fox Business - The Power to Prosper
Search Site

Wednesday, April 7, 2010 as of 11:14 AM ET

Forest Laboratories

    Forest Laboratories () is a pharmaceutical company headquartered in New York City, US. The company's research and development spending has grown rapidly in recent years, and as of 2007, approached almost a billion US dollars a year, which put it on the list of the top 100 global corporations in R&D spending.

    Read More at Wikipedia ›

    Related Topics

    1. Abbott Laboratories
    2. Ranbaxy Laboratories
    3. Watson Pharmaceuticals
    4. Miles White
    5. Icahn Enterprises
    6. Carl Icahn
    Get updates on Forest Laboratories
    The Coca-Cola Company, Walgreen Company Included in Stocks Up on High Volume Tuesday

    These stocks are up on above-average volume today:The Coca-Cola Company (NYSE:KO) experienced a price hike on above-average volume today, trading at a volume of 11 million, or 1.

    8 times its standard daily volume. Shares were up 2.1% to $73.95. The stock has risen $6.50 (9.6%) over the last three months from a price of $67.45 on January 19, 2012. The stock is trading 3.7% above its 50-day moving average and 6.6% above its 200-day moving average.Walgreen Company (NYSE:WAG) saw its price spike on above-average volume today, as 19.5 million shares, which is 2.3 times the stock's average daily volume, traded hands. Share price increased 5.3% to $35.07. Shares price has risen $2.86 (8.9%) from $32.21 on April 10, 2012. The stock has moved up across its 50-day moving average of $33.52 today.After trading at a volume of 9.3 million, or 1.9 times its average, The TJX Companies (NYSE:TJX) was up on high volume today. The stock price was up 2.9% to $41.35. The stock has moved down across its 50-d...

    Read More ›

    1. Icahn Wants All 11 Seats on Clorox Board

      Billionaire investor Carl Icahn wants all 11 seats on the board of consumer products maker Clorox Co , which has twice rejected his offers this summer to buy the com...

    2. Forest pushes new board members in fight vs Icahn

      NEW YORK (Reuters) - Forest Laboratories Inc <FRX.N> said it plans to nominate a 10-person board slate that includes three new members at its shareholder meeting, as...

    3. Analysis: After 34 years, Forest's CEO takes stand

      By Lewis KrauskopfNEW YORK (Reuters) - Forest Laboratories Inc <FRX.N> chief Howard Solomon will likely have to cede some control over the drugmaker he has stewarded...

    4. Icahn aims at longtime Forest CEO in shake-up bid

      By Lewis KrauskopfNEW YORK (Reuters) - Billionaire investor Carl Icahn is taking aim at Forest Laboratories Inc's <FRX.N> longtime chief executive officer as he seek...

    5. Takeda eyes $14.2 billion Nycomed deal: report

      By Emi Ommoto and Taro FuseTOKYO (Reuters) - Japan's Takeda Pharmaceutical Co <4502.T> is in talks to buy privately-held Swiss rival Nycomed in a deal that could be ...

    6. Forest Laboratories 3Q Profit Up on Improved Drug Sales

      Helped by higher sales of its depression, Alzheimer’s and hypertension drugs, shares of Forest Laboratories (NYSE:FRX) ticked higher on Tuesday after the company rep...

    7. Forest Laboratories' 3Q Net Up 53% As Drug Sales Rise

      Forest Laboratories Inc.'s (FRX) fiscal third-quarter profit rose 53% on strong sales of the pharmaceutical company's Alzheimer's and dementia treatment.Shares were ...

    8. Forest Labs 2Q Profit Surges on Drug Sales

      Forest Laboratories (NYSE:FRX) reported Tuesday stronger-than-expected second-quarter earnings on surging drug sales that more than offset lower contract revenues.Th...

    9. Forest Labs Posts 3Q Results, Ups Guidance

      Forest Laboratories (FRX), the maker of fibromyalgia drug Savella and blood pressure drug Bystolic, increased its earnings projection for 2010 to the high end of a r...

    1. Forest Labs 4Q Net Falls 40% As Lexapro Patent Expires; Has Upbeat Year View

      DOW JONES NEWSWIRESForest Laboratories Inc.'s (FRX) fiscal fourth-quarter earnings fell 40% as generic competition to its depression treatment Lexapro hurt sales, th...

    2. Forest Laboratories Buys Blood Pressure Drug Bystolic From Janssen For $357 Million

      DOW JONES NEWSWIRESForest Laboratories Inc. (FRX) acquired the high-blood pressure drug Bystolic from Johnson & Johnson's (JNJ) Janssen Pharmaceutica NV for a one-ti...

    3. Watson Pharma Seeks FDA Approval of Generic Version Of Bystolic

      DOW JONES NEWSWIRESWatson Pharmaceuticals Inc. (WPI) has filed an abbreviated new-drug application with the U.S. food and Drug Administration for its generic version...

    4. FDA: Forest Labs Lung Drug Effective For COPD; Raises Concerns

      The Food and Drug Administration said a proposed lung drug that would be marketed by Forest Laboratories Inc. (FRX) to treat chronic obstructive pulmonary disease wa...

    5. Teva 4Q Net Drops 34% On Acquisition Costs; Sales Up 28%

      Teva Pharmaceutical Industries Ltd.'s (TEVA) fourth-quarter profit declined 34%, as higher acquisition-related costs more than offset a revenue increase fueled by la...

    6. Forest Labs Profit Falls, Sales Up 9%

      Forest Laboratories Inc. said Tuesday its third-quarter profit fell to $278.4 million, or $1.04 a share, from $320.7 million, or $1.11 a share, in the year-ago perio...

    7. Icahn offers to backstop a Clorox auction

      By Dhanya Skariachan and Paritosh BansalNEW YORK (Reuters) - Billionaire investor Carl Icahn said on Tuesday his nominees for Clorox Co's <CLX.N> board would try to ...

    Freebase CC-BY
    Source: Forest Laboratories on Freebase, licensed under CC-BY
    Other content from Wikipedia, licensed under the GFDL